Hormone replacement therapy after prophylactic risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a meta-analysis

Mutations in DNA repair pathways, including breast-cancer susceptibility gene 1 (BRCA1) and breast-cancer susceptibility gene 2 (BRCA2) mutation carries, predispose women to an elevated lifetime risk for ovarian cancer (OC) and breast cancer (BC) (National Comprehensive Cancer Network Guidelines, 2018). While the role of bilateral risk-reducing mastectomy is still controversial, risk-reducing salpingo-oophorectomy (RRSO) represents nowadays the main effective prophylactic OC risk measure that should be proposed to BRCA carries, especially once childbearing is complete (National Comprehensive Cancer Network Guidelines, 2018; Paluch-Shimon et al., 2016; De Felice et al., 2015).

Source: Critical Reviews in Oncology Hematology - October 3, 2018 Category: Cancer & Oncology Authors: C. Marchetti, F. De Felice, S. Boccia, C. Sassu, V. Di Donato, G. Pergnola, I. Palaia, M. Monti, L. Muzii, V. Tombolini, P. Benedetti Panici Source Type: research